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Abstract
Beta (β)-lactam antibiotics are wide-spectrum antibiotics used for various bacterial infec-
tions. The aim of this chapter is to summarize the knowledge about the toxicity of β-lactam 
antibiotics and issues associated to their inappropriate use. This review has highlighted 
that β-lactam antibiotics are a group of products that have a chemical structure character-
ized by a β-lactam ring and are one of the most common antibacterial agents. However, 
due to the inappropriate use including abuse and misuse, resistance to the β-lactam anti-
biotics is currently a global crisis. Moreover, even when used appropriately, they have 
been linked to triggering allergic reactions like urticaria, bronchoconstriction, also severe 
conditions like immune-mediated haemolytic anaemia and intravascular haemolysis. It 
is known that some β-lactam antibiotics are neurotoxic, some are nephrotoxic, some are 
genotoxic and some are toxic to urogenital system. Several factors are involved in the 
occurrence of toxic effects including the dosage and renal status. Several strategies are 
possible to overcome β-lactam antibiotics-triggered toxicity, including rational prescrib-
ing, substitution combination and phage therapy which seems promising. Public health 
education for clinical teams and patients is essential in ensuring that this group of antibi-
otics are retained in therapeutics.
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1. Introduction
Beta (β)-lactam antibiotics are one of most commonly used class of antimicrobial agents 
around the world. β-lactam or β-lactamase inhibitor antibiotics are substances that disrupt 
bacterial cell-wall formation via penicillin-binding proteins (PBPs) where they bind cova-
lently at the terminal step of peptidoglycan cross-linking in bacteria [1]. The first generation 
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of β-lactam antibiotics were penicillins, followed by cephalosporins; later carbapenems and 
monocyclic β-lactams that have been recently introduced and are currently in service for the 
treatment of infectious disease caused by pathogenic bacteria [2]. However, following the 
occurrence of resistance to the penicillin, new β-lactam antibiotics are being researched for 
enhancing the spectrum efficiency against the β-lactam-resistant bacteria [3]. In terms of life-
threatening infections, β-lactam antibiotics are almost indispensable for therapies in intensive 
care units (ICUs). However, the therapy with β-lactam antibiotics remains unresolved since 
β-lactamase resistance is disseminating rapidly among pathogenic bacteria. The most serious 
types of β-lactamase resistance today are extended-spectrum β-lactamases (ESBLs), carbapen-
emases and metallo-β-lactamases (MBLs) [1, 4, 5].
The large amount of use and misuse of β-lactam antibiotics has been inducing the β-lactam 
resistance for decades; besides β-lactam antibiotics have many side or adverse effects includ-
ing allergy and toxicity [6, 7]. Since beta-lactam rings are different in their structure, they can 
be recognized by the immune system and this leads to hypersensitivity in some patients [8]. 
For example, cephalosporin can induce a range of hypersensitivity reaction and anaphylaxis 
in patients with IgE-mediated allergy [9]. Also, β-lactams are the most known causes of drug-
induced fevers [10]. β-lactam antibiotics are neurotoxic, nephrotoxic, genotoxic and some are 
reproductive toxic. The nephrotoxic effects of β-lactams lead to proximal tubular necrosis [11]. 
Some are toxic to reproductive system; tazobactam/piperacillin has a toxic effect on reproduc-
tive systems and also developmental toxicity reported that tazobactam has an influence on 
maternal toxicity [12]. Another significant point for the side effects of β-lactams is the toxicity 
on central nervous system. It can be observed after the administration of β-lactam antibiot-
ics such as penicillin; hence, clinical data have reported disorientation, twitching, somno-
lence and myoclonus [7]. β-lactam antibiotics such as imipenem and cephaloridine have been 
reported to cause an irreversible injury to the renal anionic substrate uptake and respiration 
[13]. Since this effect is dose-dependent, it can be resolved through dosing reduction based on 
renal function test results [6].
To overcome the resistance and toxicity of β-lactam antibiotics, many attempts have been 
reported. Developing more stable and more effective strategies is the key factor. For 
instance, ampicillin/sulbactam, amoxicillin/clavulanate, ticarcillin/clavulanate and piper-
acillin/tazobactam are the most used β-lactamase inhibitor combinations for clinicians [2]. 
Moreover, the selection of right β-lactam antibiotics for patients who have an antibiotic 
allergy is important. To overcome this issue, some of allergy tests are available, for example, 
penicillin skin testing [14]. Fighting with bacteria via the phage therapy is another option 
to overcome toxicity/allergy of β-lactams and it reduces the resistance risk of β-lactams. A 
unique and effective phage against metallo-β-lactamase producing Pseudomonas aeruginosa 
(P. aeruginosa) has been used to treat a catfish infection. However, this phage is not use-
ful for the treatment of infections in human [15]. By the way, combination of phages and 
antibiotics is possible; it is called phage–antibiotic synergy (PAS) and has been proven suc-
cessful in some bacteria normally resistant to β-lactam antibiotics such as cefotaxime [16]. 
Interestingly, some studies have reported that phages were not toxic on mammalian cells 
[17, 18]. Thus, the aim of this chapter is to summarize the knowledge about the  toxicity 
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of β-lactam antibiotics and issues associated to their inappropriate use. It is hoped that 
a good understanding of the structures, mechanisms of action and risk factors leading to 
resistance to β-lactam antibiotics will assist both clinicians and researchers in the design of 
anti-resistance interventions.
2. Classes of beta (β)-lactam antibiotics
Beta (β)-lactam antibiotics are a class of antibiotics that contain a β-lactam ring in their molec-
ular structures. Generally, β-lactam antibiotics have a common function: inhibition on cell-
wall biosynthesis of the peptidoglycan layer in the bacteria. And this makes β-lactams the 
most extensively used antibiotics [19]. For over 70 years, penicillin and related antibiotics 
have been used extensively for the control and treatment of bacterial infections. Improving 
the efficiency of these antibiotics is still important, and it captivates increasing attention of 
researchers to overcome the infections depending on highly resistant bacteria. Development 
of new β-lactam group of antibiotics generally depends on enhancing the spectrum efficiency 
against the pathogenic bacteria. Besides, resistance mechanisms with special features may be 
targeted [1].
Over the years, countless penicillin derivatives have been produced including penicillins, 
cephalosporins, carbapenems, oxapenems, oxacephams as well as monocyclic, spirocyclic and 
multicyclic ring systems [2]. The first β-lactam antibiotic was ‘penicillin G’ in the beginning 
of 1940s [1]. Afterwards, naturally occurring penicillin was ‘penicillin V’ which was an oral 
formulation, still in use for the therapeutic purposes. Followed by the occurring resistance to 
the penicillin, semi-synthetic penicillins were developed such as methicillin [20]. Moreover, 
some of the significant penicillins from the beginning up to date are the following: oxacillin, 
cloxacillin, ampicillin, nafcillin, amoxicillin, carbenicillin, ticarcillin, piperacillin, termocillin 
and mecillinam [20].
Cephalosporins are another subgroup of β-lactam antibiotics, and the first penicillinase-stable 
cephalosporin was discovered during 1950s [21]. It was efficient for the treatment of infectious 
diseases mainly caused by penicillinase-producing pathogenic bacteria [22]. Numerous ceph-
alosporins are in use nowadays including cefotaxime, ceftriaxone, cefepime, ceftazidime and 
cefuroxime [23]. A new addition has been made to the cephalosporin family with a sidero-
phore-substituted cephalosporin (S-649266) that contains a catechol segment which facilitates 
entry into bacterial cells through iron transportation system. Moreover, this cephalosporin is 
stable against several carbapenemases [24].
Furthermore, carbapenems are also members of the β-lactam antibiotics which act by bind-
ing to penicillin-binding proteins and lead to the inhibition of bacterial cell-wall synthesis. 
However, they have broader spectrum than other cephalosporins and have been proven suc-
cessful against Enterobacteriaceae including ESBLs [25]. Carbapenem-related agents and other 
carbapenems that have extended-spectrum activity include meropenem, imipenem, ertape-
nem and doripenem which have been used widely [1].
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Finally, at molecular level, it is worth noting that there is a peptidoglycan layer which is 
critical for bacterial cell-wall structural wholeness and stability, particularly in Gram-
positive organisms, being the outermost and primary component of the wall [26]. During 
the final stage formation of the peptidoglycan, there is a transpeptidation step catalysed by 
DD-transpeptidases which are PBPs. β-lactam antibiotics inhibit these PBPs and ultimately 
lead to cell lysis [27]. It should be noted that PBPs are classified according to their molecular 
mass: the first category is low-molecular-mass PBPs that are monofunctional, for example, 
D-Ala-D-Ala carboxypeptidases; the second category is high-molecular-mass PBPs that are 
bifunctional enzymes containing a transpeptidase (D-Ala-D-Ala-dependent) and a transgly-
cosylase [1, 28, 29].
3. Specific cases of resistance to β-lactam antibiotics
In most instances, particularly in case of life-threatening bacterial infections, antibiotics are the 
core of treatment [19]. Two of the main goals of β-lactam antibiotics are prevention and treat-
ment of bacterial infections occasioned by susceptible bacteria [1]. Antimicrobial resistance has 
a greater risk for critically ill patients. For example, it is well known that ICUs are facing a major 
problem with β-lactam antibiotics [30]. Moreover, many case studies have been reported issues 
intensively with regard to resistance to the β-lactam antibiotics. A recent case was reported 
about extensively drug-resistant (particularly β-lactams) Escherichia coli (E. coli), which was iso-
lated from the urine of a 63-year-old man from Phetchabun, Thailand. A craniotomy resulted 
that it is also difficult to treat infections like this via β-lactam antibiotics [31]. Another case was 
reported from an 87-year-old woman, who had clinical signs, for example, fever, dysuria and 
suprapubic pain. Urine culture produces a positive result for Klebsiella pneumoniae and E. coli, 
both resistant to multiple antibiotics including β-lactams [32]. β-lactam resistance can be seen 
in serious infections such as cystic fibrosis. Pollini and coworkers reported that a metallo-β-
lactamase-producing P. aeruginosa identified in a cystic fibrosis patient was resistant to car-
bapenems [33]. Furthermore, New Delhi β-lactamase-1 (NDM-1) producing Enterobacteriaceae 
infections have been found in patients suffering from type 2 diabetes mellitus infections [34]. 
Bacteria that produce NDM-1 have been dealt with resistance also in other classes of antimicro-
bials and virulently restrict treatment options [34].
It is important to note that the clinical outcomes in patients with P. aeruginosa infection are 
poor, with a case fatality rate being higher in patients with MBL-producing P. aeruginosa [35]. 
A recently approved antibiotic is ceftolozane (cephalosporin), which is a combination with 
tazobactam, has shown a potent activity and has been used successfully for treatment of the 
urinary tract and intra-abdominal infections [36]. Furthermore, there was a report from an 
organ transplant unit where a 61-year-old lung transplant patient in Chicago had Serratia marc-
escens (S. marcescens) infection with imipenem resistance. Since beta-lactam antibiotics could 
not be used, several antibiotics were prescribed instead such as trimethoprim-sulfamethoxa-
zole, itraconazole, ceftriaxone, cefepime and levofloxacin; this is clearly a costly exercise [37].
There is an observation that patients at a high risk for developing colonization with β-lactam 
resistance include both the severely ill and well-on patients. Likewise, patients with medical 
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devices like urinary catheters are also prone to antibiotic-resistant bacteria [38]. Moreover, the 
length of hospital stay is another risk factor; patients who have stayed more than 3 days in hos-
pitals and who have been previously treated with β-lactam antibiotics might be considered as 
a risk factor for the acquisition of β-lactamase resistance [39]. Furthermore, it has been reported 
in Italy that the risk factors for ESBL-producing S. marcescens and K. pneumoniae acquisition in 
neonatal ICU include low birthweight, gestational period and the use of invasive devices [40].
Further observations have noted that clinical isolates that have ESBL-produced E. coli strains 
occur generally in hospitalized patients exposed to invasive procedures [41]. It is also noted 
that when antibiotics are cheap and accessible, this encourages their overuse and subsequent 
resistance [42]. It has been reported that there is a positive relationship between antibiotic 
consumption and the emergence and spreading of resistant bacterial strains. One of the most 
significant reasons of this is the lack of enforcement of legislation which result in the sale of 
antibiotics without a prescription in many countries [43].
4. Factors and mechanisms involved in resistance to β-lactam antibiotics
Clinicians can prescribe beta-lactams without a real need; yet the health condition could 
have been treated by diet or rest. Sometimes, the consumers can take drugs without a med-
ical advice or can take more doses than prescribed doses because of mental illnesses like 
Alzheimer’s disease or dementia. Though some people know that antibiotics are used against 
bacterial infections, few are aware that antibiotics are not useful for viral infections [44]. When 
antibiotics are used in viral infections, they can trigger bacterial resistance while infections are 
not cured because of their viral background. Clinicians, surgeons, patients, consumers and 
caretakers as well require up-to-date information about the appropriate usage of β-lactam 
antibiotics because their misuse can cause severe conditions including bacterial resistance or 
allergic/toxic side effects [45].
It should be remembered that resistance to penicillin was noted in early 1940s; this finding has 
no clinical significance until the 1970s [20]. However, β-lactam resistance became a global cri-
sis nowadays [46]. Resistance to the β-lactams usually occurs by three different mechanisms: 
decreased access of antimicrobials to the target PBPs (efflux pumps), altered PBPs (affinity of 
binding decreased) and β-lactamase production [1].
Although efflux pumps are found in almost all bacterial species, the β-lactamase production 
is the most efficient of the three mechanisms. This resistance mechanism generally depends 
on plasmids that include various virulence genes consisting of multiple β-lactamases of dif-
ferent classes in this way. This is why β-lactamase resistance can sprawl among various bac-
terial species. There are two types of β-lactamases: (a) serine-β-lactamases and (b) MBLs. 
Serine-β-lactamases comprise ESBLs and carbapenemases that hydrolyse carbapenem anti-
biotics and cephalosporins [2, 20]. We can suffice to say that the most common mechanism 
for drug resistance to β-lactam antibiotics is bacterial synthesis of β-lactamases. Many bac-
teria synthesize beta-lactamases that degrade beta-lactam antibiotics before they reach the 
cell wall. Gram-positive bacteria that produce beta-lactamase excrete the enzyme into the 
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extracellular space. Gram-negative bacteria excrete beta-lactamase into the periplasmic space 
located between the cytoplasmic membrane and the outer membrane, where the cell wall is 
located; while the genes that encode beta-lactamases can be located on either (a) the bacterial 
chromosome; (b) plasmids; or (c) transposable elements which enhance the spread of beta-
lactamases among different bacterial species [47].
Carbapenemases are distinct among the β-lactamases; they are able to hydrolyse most of the 
penicillins, cephalosporins and carbapenems. In 1980s and 1990s, carbapenems were consid-
ered as the ‘last resort antibiotics’ which used primarily against ESBL- or AmpC-producing 
bacteria. Molecular classes of A, B and D β-lactamases are known as carbapenemases. The 
carbapenemase resistance generally occurs in bacteria involving OprD porin loss, overex-
pression of efflux systems, overproduction of AmpC-type β-lactamase and acquisition of car-
bapenemase-encoding genes [46]. A and D enzymes are the group of carbapenemases having 
serine-based hydrolytic mechanisms; however, the group of B carbapenemases are known 
as MBLs [48]. Also, MBLs are inhibited by chelate-divalent cations like EDTA. The group A 
carbapenemases include members of the S. marcescens enzyme (SME), imipenem-hydrolysing-
β-lactamase (IMI), not metallo-enzyme carbapenemase (NMC), Guiana-extended-spectrum 
(GES) and K. pneumoniae carbapenemases (KPC) families and their hydrolytic mechanism 
requires their active serine site at position 70 [37]. This feature gives them the ability to hydro-
lyse many β-lactam antibiotics like carbapenems, cephalosporins, penicillins and aztreonam, 
and all are inhibited by clavulanate and tazobactam [37]. SME-1 was first reported in England 
from two S. marcescens isolates. SME-1 has identical features with SME-2 and SME-3. SME-3 
β-lactamases differentiate from SME-1 gene by a single amino acid substitution of tyrosine 
for histidine at position 105 [49], and SME-1 is encoded by chromosome in blaSME−1 gene [37]. Since chromosomally encoded blaSME−1 gene was not detected in any plasmids, mobile genetic elements can be concluded that there is a limitation of SME-1 enzyme distribution [50]. The 
IMI and NMC-A enzymes have been found in clinical isolates of Enterobacter cloacae from the 
United States, Croatia, Finland and France. Most blaIMI−1 genes are located on chromosome and it is related to imi-R gene that limits their dissemination and their expression at a high level 
[51]. NMC-A and IMI-1 have 97% amino acid similarity and they are similar to the SME-1, 
with approximately 70% of amino acid identity encoded by bacterial genome B [52]. The GES 
family enzymes consist of 26 variants of GES. For example, GES-1 was reported from K. pneu-
moniae strain in year 2000. The other GES enzymes are the following: GES-2, GES-4, GES-5, 
GES-6, GES-11, GES-14 and GES-18 are able to hydrolyse imipenem. Among these enzymes, 
GES-2 and GES-5 have carbapenemase activity. K. pneumoniae carbapenemases are another 
carbepenemases, identified in K. pneumoniae. These enzymes are known as one of the most 
significant enzymes due to their effectiveness to the carbapenems [53].
OXA-type β-lactamases include Group D carbapenemases and OXA referred to oxacillin-
ases since they hydrolyse isoxazolyl penicillin oxacillin [51]. Nowadays, OXA-type enzymes 
contain over 400 enzymes. With regard to their amino acid sequences, OXA-type enzymes 
have 12 subgroups accommodating OXA-23, OXA-24/40, OXA-48, OXA-51, OXA-58, OXA-
134a, OXA-143, OXA-211, OXA-213, OXA-214, OXA-229 and OXA-235 [54]. In spite of OXA 
enzymes that were generally detected in Acinetobacter species, these enzymes were started to 
be reported in other Enterobacteriaceae members such as Salmonella spp. and P. aeruginosa; this 
showed that OXA-type β-lactamases can spread to the Enterobacteriaceae members [54–56].
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ESBLs are implicated in serine β-lactamases [48]. ESBLs are able to hydrolyse extended-spec-
trum cephalosporin; thereof they are active against the β-lactam antibiotics such as ceftazidime, 
ceftriaxone and oxyimino-monobactams. ESBLs are generally produced by Gram-negative 
bacteria including Enterobacteriaceae such as E. coli and K. pneumoniae [57]. The types of ESBLs 
are TEM- β-lactamases, SHV-β-lactamases and CTX-M-type β-lactamases. TEM-type ESBLs 
are originated from TEM-1 and TEM-2; however, the number of TEM-type ESBLs is over 100. 
The most prevalent TEM-type ESBLs were detected in E. coli and K. pneumoniae [58]. SHV-type 
ESBLs are more widespread according to the TEM-type ESBLs and more than 100 SHV-type 
ESBLs are known around the world mainly reported from Enterobacteriaceae, P. aeruginosa and 
Acinetobacter spp. CTX-M-type ESBLs have the ability to hydrolyse cefotaxime and cefepime. 
In contrast to TEM and SHV enzymes, CXT-M-type ESBLs have no point mutations in their 
structures [58]. Until today, 128 different types of CTX-M were reported such as CTX-M-1, 
CTX-M-2, CTX-M-8, CTX-M-9 and CTX-M-25. Likewise, the type of CTX-M-15 is the most 
prevalent in E. coli strains [59].
The class B MBLs can be divided into four subclasses according to their structure: (a) B1aVIM, 
imipenemase (IMP), DIM, SPM; (b) B1b: NDM, (c) B2: cphA, (d) B3: LI and AIM [37, 60]. 
Moreover, Tripoli metallo-β-lactamase (TBM-1) was also included in MBLs [58, 61]. The ear-
lier MBLs were reported in Japan in 1980s called imipenemase in P. aeruginosa [62]. After that, 
several varieties of IMP were reported such as Verona integron-encoded metallo-β-lactamase 
(VIM) and SPM-type enzymes and it was reported that VIM-producing bacteria are distrib-
uted intensely [63]. The New Delhi metallo-β-lactamase is a globally distributed enzyme dis-
covered of late. NDM was reported for the first time in year 2009 and referred to as NDM-1. 
NDM-1 can bind and hydrolyse all beta-lactams with the exception of aztreonam. There are 
13 different NDMs reported: NDM-1 to 14. The variation of these NDM types results from 
mutation within the gene encoding the β-lactamase [64]. #NDM-1 has drawn attention since 
the gene encoding these MBLs is located in a mobile genetic element and the pattern of spread 
proves to be more complex [65]. NDM can coexist with other antibiotic-resistant genes. 
Recently, plasmid-mediated NDM was reported in Thailand and coexisted with colistin 
resistance [31]. Co-carriage of ESBL, AmpC and NDM-1 genes among carbapenem-resistant 
Enterobacteriaceae in India [66] was reported. There are several MBL types reported occasion-
ally. For instance, GIM-1 MBL was reported in a clinical isolate (P. aeruginosa) in Germany in 
year 2002, firstly. In recent years, GIM-1 was started to be reported in other bacterial species 
such as S. marcescens, E. cloacae and Acinetobacter pittii [60, 67]. Similarly, SIM-1 was obtained 
uncommonly and an integron-encoded blaSIM-1 was reported from Acinetobacter baumannii 
in Korea firstly [68]. Moreover, TMB-1 was reported in an Achromobacter xylosoxidans strain 
isolated from a hospital environment sample in Tripoli, Libya [69].
5. Toxicity of β-lactam antibiotics
There are several β-lactam antibiotics, and they have various side effects (Table 1). Although 
it is very hard to gather data on all the adverse effects and present them in this section, a 
description of toxic side effects known to be associated with the use of this category of antibi-
otics is subsequently presented.
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The use of β-lactam antibiotics has been linked to triggering allergic reactions like urticaria, 
bronchoconstriction, also severe conditions like immune-mediated haemolytic anaemia and 
intravascular haemolysis [70]. It is known that some β-lactam antibiotics are neurotoxic, some 
are nephrotoxic, some are genotoxic and some are toxic to urogenital system.
Neurotoxic side effects of β-lactam antibiotics are well-known conditions for decades. The 
administration route and the dose of antibiotic are important factors that determine whether 
a neurological dysfunction would occur. β-lactam antibiotics can trigger epilepsy or seizures 
because of their chemical structures of β-lactams that make them capable of binding to the 
gamma-aminobutyric acid (GABA) receptors in the brain. Some of the β-lactams are GABA 
receptor antagonists [7]. This is the reason why penicillin injection can be used as an epilepsy 
model in rats [71]. In a case report, it was proposed that β-lactams triggered a tardive seizure 
in a patient after an electroconvulsive therapy [72]. It has been noted also that the retina is 
a target for neurotoxic pathologies. In a case report after the cataract surgery, cefuroxime 
Antibiotic Adverse/side effects Toxicity grade Populations-
circumstances
Type of study References
Cephaloglycin Nephrotoxicity Moderate Rabbit kidney extracts Experimental [13]
Imipenem Nephrotoxicity Severe Rabbit kidney extracts Experimental [13]
L-695,256 is a novel 
2-fluorenonyl 
carbapenem
Haemolytic anaemia Moderate Rhesus monkeys Experimental [70]
L-695,256 is a novel 
2-fluorenonyl 
carbapenem
Regenerative 
anaemia
Mild Squirrel monkeys Experimental [70]
Penicillin Epileptic seizures Moderate Rats Experimental [71]
Hemorrhagic cystitis Moderate Infection patient adult Case [88]
Piperacillin Nephrotoxicity Moderate 1200 patients Randomized 
control trial
[83]
Convulsion Mild Schizophrenic adult, 
ECT taken
Case [72]
Cefotiam Convulsion Mild Schizophrenic adult, 
ECT taken
Case [72]
Cefuroxime Retinal toxicity Mild Cataract patient adult Case [73]
Cefazolin Nephrotoxicity Mild Hospitalized adult 
infectious patients
Case-control [81]
Ceftriaxone Nephrotoxicity Mild Hospitalized adult 
infectious patients
Case-control [81]
Genotoxicity Moderate Human lymphocytes Experimental [85]
Amoxicillin Genotoxicity Severe Human gastric cells Experimental [86]
FCE 22891 a penem 
antibiotic
Urotoxicity Severe Rats Experimental [87]
Table 1. Illustrative adverse effects of β-lactam antibiotics.
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was given in normal dosing ranges but it induced a retinal toxicity; fortunately, the result-
ing visual loss was recovered after a week [73]. Neurotoxicity induced by β-lactams can be a 
result of renal failure, which increases the amount of the antibiotic in the circulating blood. 
Hence, even in normal dosing ranges, β-lactam antibiotics pose risks in case of renal failure 
[74]. The relationship between the nervous system and β-lactams is not just the toxicity, but 
the molecular interaction may also have positive consequences. β-lactams may have neu-
roprotective roles in some instances [75]. The molecular glutamate mechanism takes place 
for that protection [76]. Also, β-lactams can help in treating ischaemic rat brain during the 
acute phase [77]. The effect of β-lactams on the glutamate receptors affects the lab animals’ 
behaviour. Rats’ dependence on alcohol and morphine may be decreased with the β-lactam 
application [78–80].
Nephrotoxicity is a very serious side effect of antibiotics generally. β-lactam antibiotics are 
both dangerous as a mono therapy or as a combination therapy agent [81]. These chemicals 
induce toxicity in kidneys via a couple of molecular mechanisms. Tubular cells are under 
threat because of the excess active transport from blood to these cells; however, less efflux 
and accumulation happens. The other mechanism is acylation of target proteins, which cause 
respiratory arrest by inactivation of mitochondrial anionic substrate carriers in cells. The other 
nephrotoxic side effects occur via lipid peroxidation of renal cortex [11, 82]. For critically ill 
patients, it is very dangerous to use antibiotics such as tazobactam with piperacillin because 
of the toxic effect on renal tubule [83].
Genotoxic effects of some β-lactams have been shown in some studies done in vitro. 
Ceftazidime is toxic to bone marrow stromal cells via DNA polymerase inhibition [84]. 
Ceftriaxone genotoxicity was shown in human peripheral blood lymphocytes, while amoxi-
cillin genotoxicity was studied with both human lymphocytes and gastric mucosa cells result-
ing in β-lactams having genotoxicity risk [85, 86].
Also, β-lactam antibiotics have toxic effects on the urogenital system. A synthetic β-lactam 
caused urothelial hyperplasia in rats but scientist suggested that chemical is not toxic to 
human [87]. In a case study, it has been reported that penicillin-G induced haemorrhagic 
cystitis, but the patient recovered in 8 days [88]. Some of the β-lactams toxicity grades and 
possible adverse effects were shown in Table 1.
6. Strategies to overcome β-lactam antibiotic-triggered toxicity
After any toxic reaction in an organism, the resulting defects could be very severe and cannot 
be reversed; hence, there is a need for special care for recovery. When it is established that 
there is no recovery, substituting the toxic chemical or product can help reduce the risk of 
side effects.
The potential strategies to overcome β-lactam antibiotic-triggered toxicity are as follows:
1. Replacing the toxic β-lactam with a non-allergic/toxic one,
2. Using phage therapy instead of chemicals,
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3. Using β-lactamase inhibitors,
4. Using other chemicals in combination with β-lactams,
5. Performing a dialysis (for very severe cases),
6. Rational drug prescribing and treatment monitoring.
In implementing the substitution strategy, one way is to use other available β-lactam antibiot-
ics for clinical use called ESBLs such as cephalosporins, carbapenem, imipenem, monobac-
tam and aztreonam [2]. Another strategy is designing/choosing a β-lactamase inhibitor which 
makes it possible to use a smaller dose of or a mild β-lactam. Clavulanic acid, tazobactam and 
sulbactam are known inhibitors that are used for this purpose [2, 89].
With regard to phage therapy, it has always been an alternative to the antibiotics; however, the 
concerns about the production cost have made it difficult. The phage therapy has been kept on 
the shelves for decades: a less toxic option which was as effective as antibiotics [90]. But it is 
nowadays on the table as a potential replacement for β-lactam antibiotics in the near future. It 
has been successfully applied to cultured African catfish, which were infected by P. aeruginosa 
and positive results have evaluated, while there was a resistance for β-lactam antibiotics [15], 
and phage therapy may be a logical substitute for β-lactam antibiotics in the near future.
With regard to combination strategy, β-lactam antibiotics have been used with aminogly-
cosides and they created a synergistic effect, which helped to reduce the doses required for 
both groups. This strategy has been able to increase the efficiency of the β-lactam antibiotics 
[91–94]. But clinicians should be aware that, because of a possibility of unexpected adverse 
effects, dialysis facilities should be available [95].
With regard to rational prescribing, clinical teams including doctors, nurses and pharma-
cists need to work hand in hand in order to select, purchase, control, restrict and ensure that 
patients are prescribed β-lactam antibiotics only when needed and that the patients must be 
counselled on the appropriate use thereof. Considering preventive medicine perspective, it is 
cheaper trying to limit the misuse/abuse of β-lactam antibiotics.
7. Concluding remarks
The above review has highlighted that β-lactam antibiotics are a group of products that have 
a chemical structure characterized by a β-lactam ring and are one of the most common anti-
bacterial agents. However, due to inappropriate use including abuse and misuse, resistance to 
the β-lactam antibiotics is currently a global crisis. It usually occurs by three different mech-
anisms: decreased access of antimicrobials to the target PBPs (efflux pumps), altered PBPs 
(affinity of binding decreased) and β-lactamase production.
Moreover, even when used appropriately, they have been linked to triggering allergic reac-
tions like urticaria, bronchoconstriction, also severe conditions like immune-mediated hae-
molytic anaemia and intravascular haemolysis [70]. It is known that some β-lactam antibiotics 
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are neurotoxic, some are nephrotoxic, some are genotoxic and some are toxic to urogenital 
system. Several factors are involved in the occurrence of toxic effects including the dosage and 
the renal status. Several strategies to overcome β-lactam antibiotics triggered toxicity include 
rational prescribing, substitution combination and phage therapy which seems promising. 
Public health education for clinical teams and patients is essential in ensuring that this group 
of antibiotics are retained in therapeutics.
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